1. When Pathobiont-Carbohydrate Interaction Turns Bittersweet!
- Author
-
Nicolas Barnich, Benoit Chassaing, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Kenneth Rainin Foundation, National Program 'Microbiote' INSERM, Ministere de la Recherche et de la Technologie, INSERM (UMR 1071), INRAe (USC-2018, Universite Clermont Auvergne [I-SITE project (CAP 2025)], Association Francois Aupetit, ANR-18-IDEX-0001,Université de Paris,Université de Paris(2018), ANR-16-IDEX-0001,CAP 20-25,CAP 20-25(2016), European Project: ERC-2018-StG804135, ROSSI, Sabine, Université de Paris - - Université de Paris2018 - ANR-18-IDEX-0001 - IDEX - VALID, CAP 20-25 - - CAP 20-252016 - ANR-16-IDEX-0001 - IDEX - VALID, and Mucus-Penetrating Microbiota: Characterization, Mechanism and Therapeutic in Metabolic Disease - ERC-2018-StG804135 - INCOMING
- Subjects
Phosphotransferase System ,NCBI, National Center for Biotechnology Information ,PTS, phosphotransferase system ,EIIA, enzyme IIA ,Carbohydrates ,Gene Expression ,RC799-869 ,Computational biology ,Biology ,cDNA, complementary DNA ,PCR, polymerase chain reaction ,ComputingMilieux_MISCELLANEOUS ,Original Research ,Hepatology ,IBD, inflammatory bowel disease ,Gastroenterology ,RNA-seq, RNA sequencing ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Diseases of the digestive system. Gastroenterology ,Carbohydrate ,Inflammatory Bowel Diseases ,WT, wild-type ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,mRNA, messenger RNA ,IL, interleukin ,rRNA, ribosomal RNA ,Ct, cycle threshold ,BHI, brain heart infusion - Abstract
Background & Aims The inflammatory bowel diseases (IBDs), Crohn’s disease and ulcerative colitis, are caused in part by aberrant immune responses to resident intestinal bacteria. Certain dietary components, including carbohydrates, are associated with IBDs and alter intestinal bacterial composition. However, the effects of luminal carbohydrates on the composition and colitogenic potential of intestinal bacteria are incompletely understood. We hypothesize that carbohydrate metabolism by resident proinflammatory intestinal bacteria enhances their growth and worsens intestinal inflammation. Methods We colonized germ-free, wild-type, and colitis-susceptible interleukin-10 knockout mice (Il10-/-) with a consortium of resident intestinal bacterial strains and quantified colon inflammation using blinded histologic scoring and spontaneous secretion of IL12/23p40 by colon explants. We measured luminal bacterial composition using real-time 16S polymerase chain reaction, bacterial gene expression using RNA sequencing and real-time polymerase chain reaction, and luminal glucosamine levels using gas chromatography–mass spectrometry. Results We show that a consortium of 8 bacterial strains induces severe colitis in Il10-/- mice and up-regulates genes associated with carbohydrate metabolism during colitis. Specifically, Enterococcus faecalis strain OG1RF is proinflammatory and strongly up-regulates OG1RF_11616-11610, an operon that encodes genes of a previously undescribed phosphotransferase system that we show imports glucosamine. Experimental colitis is associated with increased levels of luminal glucosamine and OG1RF_11616 causes worse colitis, not by increasing E faecalis numbers, but rather by mechanisms that require the presence of complex microbiota. Conclusions Further studies of luminal carbohydrate levels and bacterial carbohydrate metabolism during intestinal inflammation will improve our understanding of the pathogenesis of IBDs and may lead to the development of novel therapies for these diseases.
- Published
- 2021